RESTEM to donate its proprietary ULSCs in an approved investigational new drug application phase I clinical study at University of Florida on Polymyositis/Dermatomyositis entitled, “LEVERAGING THE IMMUNOMODULATORY CAPACITY OF MESENCHYMAL STROMAL CELLS FOR THE THERAPY OF REFRACTORY POLYMYOSITIS AND DERMATOMYOSITIS”.
